- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01971346
The Immunological Basis for Treatment Resistance to Anti-TNF Treatments
연구 개요
상세 설명
Hypothesis: The balance between type I IFN and TNF determines the response to anti-TNF treatment. The goal of the proposed study is to address this hypothesis and demonstrate that the strength of the type I IFN signature in psoriatic skin is the major determinant of the clinical response to anti-TNF treatment.
Purpose: Determine the strength of the type I interferon and TNF signal in psoriatic skin prior to and during treatment with etanercept and correlate with degree of clinical improvement.
Study Population: up to 50 subjects, men or women over the age of 18 with clinically stable plaque psoriasis, who meet the wash out requirements and other exclusion criteria
Psoriatic patients will receive 100 mg etanercept per week (2 separate single-use pre-filled 50 mg subcutaneous injections taken on two separate days) for 3 months.
Procedures: Urine pregnancy test, TB test, photography, Physical Examinations, Skin Examinations, Study Drug, Peripheral blood and biopsies
Anticipated Results: We expect that patients with strong IFN-α signature in psoriatic skin along with weak TNF-α signature will have minimal response to anti-TNF treatment, while patients with the opposite pattern, weak IFN and strong TNF signature, will have significant clinical improvement.
연구 유형
등록 (실제)
단계
- 4단계
연락처 및 위치
연구 장소
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- University of Michigan Department of Dermatology
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- At least 18 years of age at screening.
- Clinically stable moderate to severe plaque psoriasis at screening and baseline.
Subject must be:
- A man or
- A woman who is surgically sterile or at least 3 years postmenopausal or
- A woman of childbearing potential who has had a negative pregnancy test within 7 days before the first dose of study drug.
- If the subject is sexually active, (s)he must agree to use a medically acceptable form of contraception during screening and throughout the study.
Exclusion Criteria:
- Grade 3 or 4 adverse events or infections within 28 days before screening, or between the screening visit and drug initiation.
- Active or chronic infection within 4 weeks before screening visit, or between the screening and baseline visits.
- Evidence of skin conditions other than psoriasis that would interfere with the evaluations of the effect of study medication on psoriasis.
- Use of oral psoralen with ultraviolet A (PUVA), oral retinoids, cyclosporine, alefacept, or any other systemic anti-psoriasis therapy within 28 days study drug initiation.
- Use of ulltraviolet B (UVB) therapy, topical steroids at no higher than moderate strength, topical vitamin A or D analog preparations, or anthralin with 14 days of study initiation.
- Prior or concurrent use of cyclophosphamide therapy
- Concurrent sulfasalazine therapy.
- Known hypersensitivity to Enbrel® (etanercept) or any of its components or known to have antibodies to etanercept.
- Current enrollment in any other investigational device or investigational drug trial(s), or receipt of any other investigational agent(s) within 28 days before baseline visit.
- Use of any biologic drugs within 28 days of study drug initiation.
- Concurrent use of Anakinra.
- Severe comorbidities (diabetes mellitus requiring insulin; congestive heart failure (CHF) of any severity or myocardial infarction or cerebrovascular accident or transient ischemic attack within 3 months of screening visit; unstable angina pectoris, uncontrolled hypertension (sitting systolic blood pressure (BP) <80 mm Hg or > 160 or diastolic BP > 100 mm Hg), oxygen-dependent severe pulmonary disease, history of cancer within 5 years (other than resected cutaneous basal or squamous cell carcinoma of the skin or in situ cervical cancer)
- Known history of tuberculosis (TB), or previous positive purified protein derivative (PPD) test. Any mycobacterial disease or high risk factors for tuberculosis (TB), such as family member with TB, positive purified protein derivative (PPD) or taking anti-tuberculosis medication.
- Known HIV-positive status or known history of any other immuno-suppressing disease.
- Concurrent or history of psychiatric disease that would interfere with ability to comply with study protocol or give informed consent.
- History of alcohol or drug abuse within 12 months of screening visit.
- Latex sensitivity [Nota Bene: only applicable if they are using prefilled syringe or prefilled SureClick™ autoinjector presentations]
- Exposure to hepatitis B or hepatitis C or to high risk factors for hepatitis B or C, such as intravenous drug use in patient.
- Systemic lupus erythematosus, history of multiple sclerosis, transverse myelitis, optic neuritis or seizure disorder.
- Use of a live vaccine 90 days prior to screening visit, or concurrent use of a live vaccine.
- Any condition or circumstances judged by the patient's physician[or the investigator or medically qualified study staff] to render this clinical trial detrimental or otherwise unsuitable for the patient's participation.
- History of non-compliance with other therapies.
- Pregnant or nursing females.
- Diagnosis of multiple sclerosis in first degree family relationship (parent, sibling or child)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
다른: Etanercept
100 mg Etanercept injections per week for 3 months.
|
100 mg Etanercept injections per week (2 separate single-use pre-filled 50 mg subcutaneous injections taken on two separate days) for 3 months
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Change in Psoriasis Area and Severity Index (PASI) Score
기간: Baseline, 12 weeks
|
A cumulative change in PASI score from baseline to week 12 will be calculated for each patient.
The PASI is the industry standard to decrease/eliminate subjectivity in determining psoriasis severity.
It is a quantitative rating scale for measuring the severity of psoriatic lesions based on area coverage and plaque appearance.
The severity of plaque characteristics (erythema, thickness and scaling) for body regions (head, upper limbs, trunk and lower limbs) is combined with the degree of plaque involvement in each body region to determine a single PASI score in the range of 0 (no disease) and 72 (maximal disease).
|
Baseline, 12 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Tumor Necrosis Factor (TNF)-Alpha Signal Strength
기간: Baseline, Week 6, Week 12
|
Strength of TNF-alpha signatures will be measured in skin of study subjects at initiation, during and after treatment.
The strength of these signals will be done using bioinformatic approach quantifying transcriptional signature of these cytokines.
The strength of the cytokine signals will be treated as a response variable in a univariate repeated measure analysis of variance, with PASI response profile and time as covariates.
PASI response profile will be categorized according to improvement in PASI score: responders (greater than 75% reduction in PASI from baseline), intermediate-responders (those with greater than 25% and less than 75% reduction in PASI from baseline), and non-responders (less than 25% reduction in PASI from baseline).
|
Baseline, Week 6, Week 12
|
Interferon (IFN)-Alpha Signal Strength
기간: Baseline, Week 6, Week 12
|
Strength of IFN-alpha signatures will be measured in skin of study subjects at initiation, during and after treatment.
The strength of these signals in skin will be done using bioinformatic approach quantifying transcriptional signature of these cytokines.
The strength of the cytokine signals will be treated as a response variable in a univariate repeated measure analysis of variance, with PASI response profile and time as covariates.
PASI response profile will be categorized according to improvement in PASI score: responders (greater than 75% reduction in PASI from baseline), intermediate-responders (those with greater than 25% and less than 75% reduction in PASI from baseline), and non-responders (less than 25% reduction in PASI from baseline).
|
Baseline, Week 6, Week 12
|
Psoriasis Area and Severity Index (PASI) Response Profile
기간: 12 Weeks
|
Subjects will be categorized according to improvement in Psoriasis Area and Severity Index (PASI) score: responders (greater than 75% reduction in PASI from baseline), intermediate-responders (those with greater than 25% and less than 75% reduction in PASI from baseline), and non-responders (less than 25% reduction in PASI from baseline).
|
12 Weeks
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- Derm 652
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
etanercept에 대한 임상 시험
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...완전한
-
Amgen완전한관절염, 류마티스; 관절염, 건선미국, 푸에르토 리코
-
Nanfang Hospital of Southern Medical University알려지지 않은
-
Duke UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)아직 모집하지 않음